Frizzled-8 integrates Wnt-11 and transforming growth factor-β signaling in prostate cancer

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Murillo Garzón, Virginia ^a   Gorroño Etxebarria, Irantzu ^a   Åkerfelt, Malin ^b   Puustinen, Mikael Christer ^c   Sistonen, Lea ^c   Nees, Matthias ^b   Carton, James ^b   Waxman, Jonathan ^d   Kypta, Robert M ^a,d  

^a CIC BIOGUNE   (Spain)

^b UNIVERSITY OF TURKU   (Finland)

^c ÅBO AKADEMI UNIVERSITY   (Finland)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; FRIZZLED 8 PROTEIN; FRIZZLED PROTEIN; MESSENGER RNA; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT11 PROTEIN; ATF2 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; FZD8 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; WNT PROTEIN; WNT11 PROTEIN, HUMAN;

CANCER; CELL; GENE EXPRESSION; GROWTH; PROTEIN; THREE-DIMENSIONAL MODELING;

ARTICLE; CANCER TISSUE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; MALE; PROSTATE CANCER; PROTEIN DOMAIN; UPREGULATION; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ACTIVATING TRANSCRIPTION FACTOR 2; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE SILENCING; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEINS;

EID: 85046423484     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-04042-w     Document Type: Article

References (70)

1. Siegel, R., Miller, K. &Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7-30 (2016).
2. Peter E. Lonergan, Tindall D. J. Androgen receptor signaling in prostate cancer development and progression. J. Carcinog. 10, 20 (2011).
3. Mottet, N. et al. Guidelines on prostate cancer. Eur. Assoc. Urol. https://doi. org/10.1016/j.eururo.2007.09.002 (2016).
4. Karantanos, T., Corn, P. G. &Thompson, T. C. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32, 5501-5511 (2013).
5. Chandrasekar, T., Yang, J. C., Gao, A. C. &Evans, C. P. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl. Androl. Urol. 4, 365-380 (2015).
6. Logan, C. &Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20, 781-810 (2004).
7. Clevers, H. Wnt/β-catenin signaling in development and disease. Cell 127, 469-480 (2006).
8. Anastas, J. N. &Moon, R. T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13, 11-26 (2013).
9. Niehrs, C. The complex world of WNT receptor signalling. Mol. Cell Biol. 13, 767-779 (2012).
10. Komiya, Y. &Habas, R. Wnt signal transduction pathways. Organogenesis 4, 68-75 (2008).
11. Veeman, M. T., Axelrod, J. D. &Moon, R. T. A second canon: functions and mechanisms of β-catenin-independent Wnt signaling. Dev. Cell 5, 367-377 (2003).
12. Eferl, R. &Wagner, E. F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3, 859-868 (2003).
13. Kohn, A. D. &Moon, R. T. Wnt and calcium signaling: beta-cateninindependent pathways. Cell Calcium 38, 439-446 (2005).
14. Uysal-Onganer, P. &Kypta, R. M. Wnt11 in 2011\-The regulation and function of a non-canonical Wnt. Acta Physiol. 204, 52-64 (2012).
15. Flaherty, M. P. et al. Noncanonical Wnt11 signaling is sufficient to induce cardiomyogenic differentiation in unfractionated bone marrow mononuclear cells. Circulation 117, 2241-2252 (2008).
16. Zhou, W. et al. Modulation of morphogenesis by noncanonical Wnt signaling requires ATF/CREB family-mediated transcriptional activation of TGFβ2. Nat. Genet. 39, 1225-1234 (2007).
17. Ohkawara, B. &Niehrs, C. An ATF2-based luciferase reporter to monitor non-canonical Wnt signaling in Xenopus embryos. Dev. Dyn. 240, 188-194 (2011).
18. Geetha-Loganathan, P., Nimmagadda, S., Fu, K. &Richman, J. M. Avian facial morphogenesis is regulated by c-Jun N-terminal Kinase/planar cell polarity (JNK/PCP) wingless-related (WNT) signaling. J. Biol. Chem. 289, 24153-24167 (2014).
19. Railo, A., Nagy, I., Kilpeläinen, P. &Vainio, S. Wnt-11 signaling leads to down-regulation of the Wnt/beta-catenin, JNK/AP-1 and NF-kappaB pathways and promotes viability in the CHO-K1 cells. Exp. Cell Res. 314, 2389-2399 (2008).
20. Maye, P., Zheng, J., Li, L. &Wu, D. Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway. J. Biol. Chem. 279, 24659-24665 (2004).
21. Djiane, A., Riou, J.-F. R., Umbhauer, M., Boucaut, J.-C. &Shi, D.-L. Role of Frizzled 7 in the regulation of convergent extension movements during gastrulation in Xenopus laevis. Development 127, 3091-3100 (2000).
22. Yamanaka, H. &Nishida, E. Wnt11 stimulation induces polarized accumulation of Dishevelled at apical adherens junctions through Frizzled 7. Genes Cells 12, 961-967 (2007).
23. Cavodeassi, F. et al. Early stages of zebrafish eye formation require the coordinated activity of Wnt11, Fz5, and the Wnt/β-catenin pathway. Neuron 47, 43-56 (2005).
24. Ye, X., Wang, Y., Rattner, A. &Nathans, J. Genetic mosaic analysis reveals a major role for Frizzled 4 and Frizzled 8 in controlling ureteric growth in the developing kidney. Development 138, 1161-1172 (2011).
25. Grumolato, L. et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev. 24, 2517-2530 (2010).
26. Bai, Y. et al. Ror2 receptor mediates wnt11 ligand signaling and affects convergence and extension movements in zebrafish. J. Biol. Chem. 289, 20664-20676 (2014).
27. Kim, G., Her, J. &Han, J. Ryk cooperates with Frizzled 7 to promote Wnt11-mediated endocytosis and is essential for Xenopus laevis convergent extension movements. J. Cell Biol. 182, 1073-1082 (2008).
28. Zhu, H. et al. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen. Receptor 64, 7918-7926 (2004).
29. Uysal-Onganer, P. et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol. Cancer 9, 55 (2010).
30. Gupta, S. et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 70, 6735-6745 (2010).
31. Wang, H. Q., Xu, M. L., Ma, J., Zhang, Y. &Xie, C. H. Frizzled-8 as a putative therapeutic target in human lung cancer. Biochem. Biophys. Res. Commun. 417, 62-66 (2012).
32. Yin, S. et al. Tumor Initiating Cells and FZD8 play a major role in drug resistance in triple-negative breast cancer. Mol. Cancer Ther. 12, 491-498 (2013).
33. Zhang, H. et al. Protein tyrosine kinase 7 (PTK7) as a predictor of lymph node metastases and a novel prognostic biomarker in patients with prostate cancer. Int. J. Mol. Sci. 15, 11665-11677 (2014).
34. Pascal, L. E. et al. Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer 9, 452 (2009).
35. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
36. Abeshouse, A. et al. The molecular taxonomy of primary prostate. Cancer Cell 163, 1011-1025 (2015).
37. Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215-1228 (2015).
38. Sun, S. et al. Targeting the c-Met/FZD8 signaling axis eliminates patientderived cancer stem-like cells in head and neck squamous carcinomas. Cancer Res. 74, 7546-7559 (2014).
39. Mikels, A. &Nusse, R. Wnts as ligands: processing, secretion and reception. Oncogene 25, 7461-7468 (2006).
40. Lee, H.-J. et al. Structure-based discovery of novel small molecule Wnt signaling inhibitors by targeting the cysteine rich domain of Frizzled. J. Biol. Chem. 290, 30596-30606 (2015).
41. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442-454 (2002).
42. Zhang, P., Cai, Y., Soofi, A. &Dressler, G. R. Activation of Wnt11 by transforming growth factor-β drives mesenchymal gene expression through non-canonical Wnt protein signaling in renal epithelial cells. J. Biol. Chem. 287, 21290-21302 (2012).
43. Härma, V. et al. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS ONE 5, e10431 (2010).
44. Lokman, N. A., Elder, A. S. F., Ricciardelli, C. &Oehler, M. K. Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. Int. J. Mol. Sci. 13, 9959-9970 (2012).
45. Wei, J. et al. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via Src regulation. Anticancer Res. 28, 327-334 (2008).
46. Singh, S., Sadacharan, S. &Su, S. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res. 63, 2306-2311 (2003).
47. Taylor, B., Schultz, N. &Hieronymus, H. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
48. Guo, X. &Wang, X.-F. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 19, 71-88 (2009).
49. Attisano, L. &Wrana, J. L. Signal integration in TGF-β, WNT, and Hippo pathways. F1000Prime Rep. 5, 17 (2013).
50. Padua, D. &Massagué, J. Roles of TGFbeta in metastasis. Cell Res. 19, 89-102 (2009).
51. Wendt, M. K., Allington, T. M. &Schiemann, W. P. Mechanisms of epithelialmesenchymal transition by TGF-β. Future Oncol. 5, 1145-1168 (2009).
52. Sano, Y. et al. ATF-2 is a common nuclear target of smad and TAK1 pathways in transforming growth factor-β signaling. J. Biol. Chem. 274, 8949-8957 (1999).
53. Vinson, C. et al. Classification of human B-ZIP proteins based on dimerization properties. ASHA 22, 6321-6335 (2002).
54. Shi, Y. &Massagué, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003).
55. Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C. &Garcia, K. C. Structural basis of Wnt recognition by Frizzled. Science 337, 59-64 (2012).
56. Gurney, A. et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl Acad. Sci. USA 109, 11717-11722 (2012).
57. Wei, W., Chua, M.-S., Grepper, S. &So, S. K. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol. Cancer 10, 16 (2011).
58. Spanjer, A. I. R. et al. TGFβ-induced profibrotic signaling is regulated in part by the WNT receptor Frizzled-8. FASEB J. 30, 1823-1835 (2016).
59. Li, Q. et al. FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/β-catenin signaling. Cancer Lett. 402, 166-176 (2017).
60. Mihara, E. et al. Active and water-soluble form of lipidated Wnt protein is maintained by a serum glycoprotein afamin/α-albumin. eLife 5, e11621 (2016).
61. Vivanco, M. D., Johnson, R., Galante, P. E., Hanahan, D. &Yamamoto, K. R. A transition in transcriptional activation by the glucocorticoid and retinoic acid receptors at the tumor stage of dermal fibrosarcoma development. EMBO J. 14, 2217-2228 (1995).
62. Dennler, S., Itoh, S., Vivien, D., Dijke, P. &Gauthier, J. Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1. Gene 17, 3091-3100 (1998).
63. van der Sanden, M. H. M., Meems, H., Houweling, M., Helms, J. B. &Vaandrager, A. B. Induction of CCAAT/enhancer-binding protein (C/EBP)-homologous protein/growth arrest and DNA damage-inducible protein 153 expression during inhibition of phosphatidylcholine synthesis is mediated via activation of a C/EBP-activating transcription factor-r. J. Biol. Chem. 279, 52007-52015 (2004).
64. Yu, H., Ye, X., Guo, N. &Nathans, J. Frizzled 2 and Frizzled 7 function redundantly in convergent extension and closure of the ventricular septum and palate: evidence for a network of interacting genes. Development 139, 4383-4394 (2012).
65. Rishi, V. et al. SREBP-1 dimerization specificity maps to both the helix-loophelix and leucine zipper domains: use of a dominant negative. J. Biol. Chem. 279, 11863-11874 (2004).
66. Wrana, J. et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71, 1003-1014 (1992).
67. Feng, X. &Derynck, R. Ligand-independent activation of transforming growth factor (TGF) beta signaling pathways by heteromeric cytoplasmic domains of TGF-beta receptors. J. Biol. Chem. 271, 13123-13129 (1996).
68. Semenov, M. V. et al. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr. Biol. 11, 951-961 (2001).
69. Simões, B. et al. Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res. Treat. 129, 23-25 (2011).
70. Härma, V. et al. Quantification of dynamic morphological drug responses in 3D organotypic cell cultures by automated image analysis. PLoS ONE 9, e96426 (2014).